Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) was the recipient of a significant drop in short interest in June. As of June 30th, there was short interest totalling 3,576,242 shares, a drop of 37.3% from the June 15th total of 5,705,275 shares. Based on an average trading volume of 768,948 shares, the days-to-cover ratio is presently 4.7 days. Currently, 6.0% of the company’s stock are short sold.

ARLZ has been the topic of a number of recent research reports. ValuEngine cut shares of Aralez Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. Bloom Burton raised shares of Aralez Pharmaceuticals from an “accumulate” rating to a “buy” rating in a report on Monday, April 10th.

Aralez Pharmaceuticals (NASDAQ ARLZ) opened at 1.52 on Friday. Aralez Pharmaceuticals has a 52-week low of $1.09 and a 52-week high of $6.80. The stock’s market capitalization is $100.08 million. The company has a 50-day moving average of $1.33 and a 200-day moving average of $2.82.

Aralez Pharmaceuticals (NASDAQ:ARLZ) last issued its earnings results on Tuesday, May 9th. The company reported ($0.42) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.40) by $0.02. Aralez Pharmaceuticals had a negative return on equity of 66.74% and a negative net margin of 133.92%. The company had revenue of $26 million during the quarter, compared to analyst estimates of $20.23 million. During the same period in the prior year, the business earned ($0.73) earnings per share. Aralez Pharmaceuticals’s quarterly revenue was up 221.0% on a year-over-year basis. Equities research analysts expect that Aralez Pharmaceuticals will post ($1.56) EPS for the current year.

In other Aralez Pharmaceuticals news, Director Jason Aryeh sold 388,685 shares of the firm’s stock in a transaction that occurred on Tuesday, May 23rd. The shares were sold at an average price of $1.44, for a total transaction of $559,706.40. Following the sale, the director now owns 15,000 shares of the company’s stock, valued at $21,600. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Arthur S. Kirsch acquired 50,000 shares of the business’s stock in a transaction on Wednesday, June 14th. The shares were bought at an average cost of $1.17 per share, for a total transaction of $58,500.00. Following the acquisition, the director now owns 206,609 shares of the company’s stock, valued at approximately $241,732.53. The disclosure for this purchase can be found here. In the last ninety days, insiders sold 558,311 shares of company stock worth $777,214. 6.70% of the stock is owned by corporate insiders.

A number of large investors have recently modified their holdings of the company. Franklin Street Advisors Inc. NC raised its stake in shares of Aralez Pharmaceuticals by 67.5% in the second quarter. Franklin Street Advisors Inc. NC now owns 99,229 shares of the company’s stock valued at $134,000 after buying an additional 40,000 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Aralez Pharmaceuticals by 0.3% in the first quarter. Goldman Sachs Group Inc. now owns 121,494 shares of the company’s stock valued at $260,000 after buying an additional 354 shares in the last quarter. FNY Managed Accounts LLC raised its stake in shares of Aralez Pharmaceuticals by 4.2% in the first quarter. FNY Managed Accounts LLC now owns 77,119 shares of the company’s stock valued at $165,000 after buying an additional 3,136 shares in the last quarter. Broadfin Capital LLC raised its stake in shares of Aralez Pharmaceuticals by 8.3% in the first quarter. Broadfin Capital LLC now owns 5,191,590 shares of the company’s stock valued at $11,110,000 after buying an additional 400,000 shares in the last quarter. Finally, KCG Holdings Inc. bought a new stake in shares of Aralez Pharmaceuticals during the first quarter valued at $310,000. 35.64% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Aralez Pharmaceuticals Inc. (ARLZ) Short Interest Update” was published by American Banking News and is the property of of American Banking News. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark & copyright law. The correct version of this story can be read at https://www.americanbankingnews.com/2017/07/16/aralez-pharmaceuticals-inc-arlz-short-interest-update.html.

Aralez Pharmaceuticals Company Profile

Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.

Receive News & Ratings for Aralez Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.